FDA approves the four-dose Zepbound KwikPen, putting a month of tirzepatide in one device

Eli Lilly said on February 23, 2026 that the U.S. Food and Drug Administration approved a label expansion for Zepbound (tirzepatide) to add a four-dose, single-patient-use KwikPen that delivers a full month of treatment in one device ^[1]. Patients with a valid prescription who pay out of pocket through LillyDirect can get any Zepbound dose in either the KwikPen or a single-dose vial at the same self-pay price, starting at $299 per month for the 2.5 mg dose ^[1].

The KwikPen replaces the current arrangement of four separate single-dose autoinjectors per month with one dial-style pen that contains all four weekly doses ^[2]. The design is closer to an insulin pen than to the fixed-dose Zepbound pen many people use now ^[2]. Zepbound remains available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg ^[1]. The 2.5 mg strength is a starting dose and is not an approved maintenance dose; approved maintenance doses are 5 mg, 10 mg or 15 mg once weekly for weight reduction, and 10 mg or 15 mg for obstructive sleep apnea ^[1].

What it costs

On Lilly's LillyDirect page, KwikPen self-pay prices are listed as $299 a month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg, 10 mg, 12.5 mg and 15 mg when the prescription is refilled within 45 days under the Zepbound Journey Program ^[3]. If a refill comes later than 45 days, regular prices apply: $499 for 7.5 mg, and $699 each for 10 mg, 12.5 mg and 15 mg ^[3]. For the KwikPen, Lilly defines a month as 28 days and one single-patient-use pen ^[3]. Every KwikPen listing carries the note "Pen needle purchase required" ^[3]. That is a change from the single-dose Zepbound pen, where Lilly's page says a needle is included in each pen ^[3].

The sources are not fully consistent on how you can get the KwikPen. One trade report says it is currently available only through LillyDirect Pharmacy ^[2]. Lilly's own product page labels the KwikPen "Select insurance accepted | Self-pay accepted" and points eligible Medicare Part D patients with a KwikPen prescription to a Medicare GLP-1 Bridge program ^[3]. How widely commercial insurance will cover the new device is not spelled out in these sources.

Why it matters for patients

The biggest practical difference is how the device is handled. According to pharmacy coverage of the launch, the Zepbound KwikPen should be primed before each injection, similar to insulin pens ^[2]. That differs from semaglutide pens such as Ozempic and Wegovy, which are primed only once with a new pen, and from the no-priming Zepbound single-dose autoinjector ^[2]. Anyone moving from a semaglutide product may not expect a priming step every week, which the report flags as an important counseling point ^[2]. Pen needles are not in the box and require a separate prescription or over-the-counter purchase ^[2][3].

Cost math also shifts. Self-pay pricing is identical for KwikPen and vials at each strength ^[1][3], but vials require buying needles and syringes separately, while the single-dose pen route is the one Lilly lists as insurance-accepted with a co-pay as low as $25 a month for up to a three-month prescription for eligible commercially insured patients ^[3]. Government beneficiaries are excluded from that offer ^[3].

One safety point applies specifically to multi-dose devices: Lilly says not to share a KwikPen with other people, even if the pen needle has been changed, because of infection risk ^[1].

Zepbound's efficacy data are unchanged by this approval. In SURMOUNT-1, adults on 15 mg lost an average of 20.9% of body weight over 72 weeks versus 3.1% on placebo ^[1]. In the open-label SURMOUNT-5 trial, people on a maximum tolerated Zepbound dose lost an average of 20.2% (50 pounds) compared with 13.7% (33 pounds) on injectable Wegovy (semaglutide) ^[1].

What happens next

Lilly says the KwikPen is available now by prescription through LillyDirect ^[1]. The company reported that more than 1 million patients accessed Lilly treatments through LillyDirect in 2025, and that one of every three new patients starting a branded weight management medication was prescribed Zepbound self-pay vials that year ^[1]. Whether retail pharmacies will stock the KwikPen, and what pen needles will add to monthly cost, is not addressed in these sources.